Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Garrido P1, Conde E2, de Castro J3, Gómez-Román JJ4, Felip E5, Pijuan L6, Isla D7, Sanz J8, Paz-Ares L9, López-Ríos F2.

Author information

1: Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Universidad Alcalá, IRYCIS, CIBERONC, Ctra. de Colmenar Viejo, km. 9100, 28034, Madrid, Spain. pilargarridol@gmail.com.
2: Department of Pathology-Laboratorio de Dianas Terapéuticas, Hospital Universitario HM Sanchinarro, CIBERONC, Madrid, Spain.
3: Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain.
4: Department of Pathology, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, IDIVAL, Santander, Spain.
5: Department of Medical Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
6: Department of Pathology, Hospital del Mar, Barcelona, Spain.
7: Department of Medical Oncology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
8: Department of Pathology, Facultad de Medicina, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Universidad Complutense de Madrid, Madrid, Spain.
9: Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.

Abstract

In 2011 the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) started a joint project to establish guidelines on biomarker testing in patients with advanced non-small-cell lung cancer (NSCLC) based on current evidence. As this field is constantly evolving, these guidelines have been updated, previously in 2012 and 2015 and now in 2019. Current evidence suggests that the mandatory tests to conduct in all patients with advanced NSCLC are for EGFR and BRAF mutations, ALK and ROS1 rearrangements and PD-L1 expression. The growing need to study other emerging biomarkers has promoted the routine use of massive sequencing (next-generation sequencing, NGS). The coordination of every professional involved and the prioritisation of the most suitable tests and technologies for each case remains a challenge.